Company news

Csl Limited (ASX:CSL) news

Csl Limited news releases on 6ix. Latest, Oct 5, 2026: CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney…

Csl Limited (ASX:CSL) news

Press releases & updates

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

CSL enters exclusive agreement with Alentis Therapeutics

CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

CSL : Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing

World’s-First Battery-Powered Self-Unloading Bulk Carrier Now Operating in South Australia

CSL Results Presentation for FY2026

CSL : European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries

CSL Marks the Completion of the First Vessel in World-Leading Transhipment Fleet for Simandou Project

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

CSL Delivers World’s First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations

CSL Takes Delivery of MV CSL Kuleana, Advancing CSL International Pool Newbuild Program

CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada

Vaccine Adjuvant Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | CSL Limited, Seppic

CSL : Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older

CSL : Seqirus Signs Long-Term Agreement with the Pan American Health Organization (PAHO) to Advance Pandemic Influenza Preparedness in Latin America and the Caribbean

Interim CEO 90 Day Review and Financial Update

CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of the Americas

CSL : Seqirus Signs Long-Term Agreement with The Pan American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas

CSL announces expansion of Illinois plasma therapy manufacturing facility

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

CSL : Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

CSL : Neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia

CSL Half Year Results Investor Presentation

CSL Statutory Accounts for the Half Year Ended 31 December

CSL Half Year Results Announcement

Paul McKenzie retires, Gordon Naylor appointed interim CEO

Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

CSL : to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies

CSL Capital Markets Day

CSL : Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic influenza vaccines

CSL 2025 AGM Chair and CEO Speech and Presentation

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

CSL : Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025

CSL : near-term emissions reduction targets validated by the SBTi

CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment

CSL partners on new coagulation treatment

CSL FY25 Results and Major Strategic Initiatives

CSL Results Presentation

CSL Statutory Accounts for FY2025

Health Canada Has Authorized CSL's ANDEMBRY(R) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)

Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy